List view / Grid view
The proposed approach demonstrates benefit for real-world application, establishing more robust, adaptive, and economical process systems, the research suggests.
As part of the agreement with Novo Nordisk, Lexicon Pharmaceuticals is eligible for total of $1 billion in upfront and potential milestone payments, alongside royalties.
31 March 2025 | By
Learn how Medtronic processes and quantifies their xC/UV/MS data using the quantitation workflow in MS Workbook Suite.
EPR's latest Pharma Horizons report explores the latest advances in artificial intelligence (AI) for drug and clinical development, regulation and more.
Immigration law experts from Fragomen LLP discuss currently challenges in the UK’s visa system and propose recommendations for attracting science and technology talent that support the country’s competitiveness.
Biotechnology Innovation Organization (BIO) and the International Generic and Biosimilar medicines Association (IGBA) highlight the need for industry cooperation to support the potential impact of tarrifs.
The drug is the first in a new class of oral antibiotics for uncomplicated urinary tract infections in nearly three decades.
26 March 2025 | By Thermo Fisher Scientific Pharma Services
This webinar explores oral drug product development and how to address critical challenges such as complex formulations and regulatory hurdles.
The new license agreement will support development of a potential additional treatment option for patients at risk of atherosclerosis.
The research highlights a potential approach to address cross-contamination challenges during cell-processing operations.
The anti-amyloid drug study highlights the importance of longer-term follow-up to determine benefits and risks of dementia treatments.
EPR Issue 1 includes articles on manufacturing, drug delivery, process analytical technology (PAT), RNA therapeutics and more.
The new data shows potential of the psilocybin treatment to provide durable, longer-term antidepressant effects in patients with treatment-resistant depression (TRD).
The company’s new acquisition, valued up to $1 billion, supports development of in vivo cancer treatments and the future of cell therapy.
The throughput achieved by the researchers exceeded that of other reported methods by orders of magnitude, supporting the advancement of precision nanomaterials.
